- Home
- GDTC vs PPCB Comparison
GDTC vs PPCB Comparison
Compare GDTC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- PPCB
- Stock Information
- Founded
- GDTC 2018
- PPCB 2007
- Country
- GDTC Singapore
- PPCB Australia
- Employees
- GDTC N/A
- PPCB N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- PPCB
- Sector
- GDTC Health Care
- PPCB
- Exchange
- GDTC Nasdaq
- PPCB Nasdaq
- Market Cap
- GDTC 24.2M
- PPCB 23.4M
- IPO Year
- GDTC 2023
- PPCB N/A
- Fundamental
- Price
- GDTC $2.28
- PPCB $1.58
- Analyst Decision
- GDTC Buy
- PPCB
- Analyst Count
- GDTC 1
- PPCB 0
- Target Price
- GDTC $5.00
- PPCB N/A
- AVG Volume (30 Days)
- GDTC 105.3K
- PPCB 353.1K
- Earning Date
- GDTC 01-01-0001
- PPCB 09-30-2025
- Dividend Yield
- GDTC N/A
- PPCB N/A
- EPS Growth
- GDTC N/A
- PPCB N/A
- EPS
- GDTC N/A
- PPCB N/A
- Revenue
- GDTC $573,193.00
- PPCB N/A
- Revenue This Year
- GDTC $5.37
- PPCB N/A
- Revenue Next Year
- GDTC N/A
- PPCB N/A
- P/E Ratio
- GDTC N/A
- PPCB N/A
- Revenue Growth
- GDTC 63.03
- PPCB N/A
- 52 Week Low
- GDTC $1.65
- PPCB $1.25
- 52 Week High
- GDTC $4.05
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- GDTC 61.26
- PPCB N/A
- Support Level
- GDTC $1.95
- PPCB N/A
- Resistance Level
- GDTC $2.43
- PPCB N/A
- Average True Range (ATR)
- GDTC 0.18
- PPCB 0.00
- MACD
- GDTC 0.02
- PPCB 0.00
- Stochastic Oscillator
- GDTC 71.00
- PPCB 0.00
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.